XERSXeris Biopharma Holdings Inc
XERS
Xeris Biopharma Holdings Inc10,696
Mkt Cap
$1.03BVolume
1.09M52W High
$10.0852W Low
$3.95PE Ratio
-796.00XERS Fundamentals
Price
$6.07Prev Close
$5.97Open
$5.9750D MA
$6.20Beta
1.26Avg. Volume
2.11MEPS (Annual)
$0.0032P/B
72.49Rev/Employee
$670,908.05$1,503.09
Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS
Apella Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2,359.0% during the fourth quarter, according to the company in its most recent...
MarketBeat·7d ago
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an...
MarketBeat·10d ago
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at...
MarketBeat·11d ago
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris Board of...
Business Wire·11d ago
Xeris Biopharma (NASDAQ:XERS) Director James Aloysius Brady Sells 10,834 Shares
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director James Aloysius Brady sold 10,834 shares of the firm's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the sale, the...
MarketBeat·11d ago
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director James Aloysius Brady sold 10,834 shares of the stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the...
MarketBeat·12d ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating...
MarketBeat·16d ago
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4% - What's Next?
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.4% - Should You Buy...
MarketBeat·19d ago
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC
Granahan Investment Management LLC purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the third quarter, according to its most recent disclosure with the SEC...
MarketBeat·28d ago
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Divisadero Street Capital Management LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·29d ago
<
1
2
...
>